Genprex Preclinical Data Show 79% Tumor Shrinkage and Biomarker Insight for Lung Cancer
Researchers identified low TROP2 and high PTEN levels as biomarkers of primary resistance to Reqorsa in half of NSCLC cell lines and PDX models, informing precision medicine strategies. In ALK+ NSCLC mouse models, Reqorsa achieved 79% tumor shrinkage and, with alectinib, produced synergistic tumor reductions and NK cell activation.
1. Biomarker Discovery
Researchers screened 10 NSCLC cell lines, PDX-derived organoids and xenografts treated with Reqorsa and found 50% exhibited primary resistance. Reverse-phase protein array analysis of 500 proteins in resistant models revealed low TROP2 and high PTEN expression as potential predictive biomarkers for patient selection in future trials.
2. In Vitro and In Vivo Efficacy
In ALK-EML4 positive NSCLC cell lines, Reqorsa induced apoptosis and reduced tumor volume, including models resistant to alectinib. In mouse studies, Reqorsa alone achieved up to 79% tumor shrinkage, while the combination with alectinib showed a synergistic effect yielding a 23% improvement over alectinib monotherapy.
3. NK Cell Activation
Restoring TUSC2 function via Reqorsa enhanced natural killer cell cytotoxicity in vitro and in vivo, leading to marked tumor suppression and complete elimination in some models. These findings support Reqorsa’s potential as both a standalone therapy and an adjunct to re-sensitize resistant lung cancers.